Optimal Timing of Cabazitaxel Introduction for Japanese Patients with Metastatic Castration-resistant Prostate Cancer

Toshiki Ito, Kent Kanao, Kiyoshi Takahara, Ryosuke Ando, Takahiro Yasui, Ryoichi Shiroki, Makoto Sumitomo, Hideaki Miyake

Research output: Contribution to journalArticle

Abstract

Background/Aim: Limited information is available to help physicians decide when to introduce cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) patients. The objective of this study was to assess the optimal timing of cabazitaxel introduction. Patients and Methods: The clinical outcomes of 66 mCRPC patients receiving cabazitaxel following failure of docetaxel were retrospectively analyzed. Results: Among the parameters possibly affecting the timing of cabazitaxel introduction, only an increased prostate-specific antigen (PSA) value from the diagnosis of CRPC had a significant impact on overall survival (OS) after the introduction of cabazitaxel. Furthermore, there was a significant correlation between the increased PSA value from the diagnosis of CRPC and the baseline PSA value at cabazitaxel introduction. Multivariate analysis showed that only the baseline PSA value at cabazitaxel introduction is an independent predictor of OS. Conclusion: A comparatively low PSA value could be an alternative index suggesting the optimal timing for cabazitaxel introduction.

Original languageEnglish
Pages (from-to)3089-3094
Number of pages6
JournalAnticancer research
Volume39
Issue number6
DOIs
Publication statusPublished - 01-01-2019

Fingerprint

Castration
Prostatic Neoplasms
Prostate-Specific Antigen
docetaxel
Survival
cabazitaxel
Multivariate Analysis
Physicians

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ito, Toshiki ; Kanao, Kent ; Takahara, Kiyoshi ; Ando, Ryosuke ; Yasui, Takahiro ; Shiroki, Ryoichi ; Sumitomo, Makoto ; Miyake, Hideaki. / Optimal Timing of Cabazitaxel Introduction for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. In: Anticancer research. 2019 ; Vol. 39, No. 6. pp. 3089-3094.
@article{2880d3a9f41346ec9003e59f7306b93b,
title = "Optimal Timing of Cabazitaxel Introduction for Japanese Patients with Metastatic Castration-resistant Prostate Cancer",
abstract = "Background/Aim: Limited information is available to help physicians decide when to introduce cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) patients. The objective of this study was to assess the optimal timing of cabazitaxel introduction. Patients and Methods: The clinical outcomes of 66 mCRPC patients receiving cabazitaxel following failure of docetaxel were retrospectively analyzed. Results: Among the parameters possibly affecting the timing of cabazitaxel introduction, only an increased prostate-specific antigen (PSA) value from the diagnosis of CRPC had a significant impact on overall survival (OS) after the introduction of cabazitaxel. Furthermore, there was a significant correlation between the increased PSA value from the diagnosis of CRPC and the baseline PSA value at cabazitaxel introduction. Multivariate analysis showed that only the baseline PSA value at cabazitaxel introduction is an independent predictor of OS. Conclusion: A comparatively low PSA value could be an alternative index suggesting the optimal timing for cabazitaxel introduction.",
author = "Toshiki Ito and Kent Kanao and Kiyoshi Takahara and Ryosuke Ando and Takahiro Yasui and Ryoichi Shiroki and Makoto Sumitomo and Hideaki Miyake",
year = "2019",
month = "1",
day = "1",
doi = "10.21873/anticanres.13444",
language = "English",
volume = "39",
pages = "3089--3094",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

Optimal Timing of Cabazitaxel Introduction for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. / Ito, Toshiki; Kanao, Kent; Takahara, Kiyoshi; Ando, Ryosuke; Yasui, Takahiro; Shiroki, Ryoichi; Sumitomo, Makoto; Miyake, Hideaki.

In: Anticancer research, Vol. 39, No. 6, 01.01.2019, p. 3089-3094.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Optimal Timing of Cabazitaxel Introduction for Japanese Patients with Metastatic Castration-resistant Prostate Cancer

AU - Ito, Toshiki

AU - Kanao, Kent

AU - Takahara, Kiyoshi

AU - Ando, Ryosuke

AU - Yasui, Takahiro

AU - Shiroki, Ryoichi

AU - Sumitomo, Makoto

AU - Miyake, Hideaki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Aim: Limited information is available to help physicians decide when to introduce cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) patients. The objective of this study was to assess the optimal timing of cabazitaxel introduction. Patients and Methods: The clinical outcomes of 66 mCRPC patients receiving cabazitaxel following failure of docetaxel were retrospectively analyzed. Results: Among the parameters possibly affecting the timing of cabazitaxel introduction, only an increased prostate-specific antigen (PSA) value from the diagnosis of CRPC had a significant impact on overall survival (OS) after the introduction of cabazitaxel. Furthermore, there was a significant correlation between the increased PSA value from the diagnosis of CRPC and the baseline PSA value at cabazitaxel introduction. Multivariate analysis showed that only the baseline PSA value at cabazitaxel introduction is an independent predictor of OS. Conclusion: A comparatively low PSA value could be an alternative index suggesting the optimal timing for cabazitaxel introduction.

AB - Background/Aim: Limited information is available to help physicians decide when to introduce cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) patients. The objective of this study was to assess the optimal timing of cabazitaxel introduction. Patients and Methods: The clinical outcomes of 66 mCRPC patients receiving cabazitaxel following failure of docetaxel were retrospectively analyzed. Results: Among the parameters possibly affecting the timing of cabazitaxel introduction, only an increased prostate-specific antigen (PSA) value from the diagnosis of CRPC had a significant impact on overall survival (OS) after the introduction of cabazitaxel. Furthermore, there was a significant correlation between the increased PSA value from the diagnosis of CRPC and the baseline PSA value at cabazitaxel introduction. Multivariate analysis showed that only the baseline PSA value at cabazitaxel introduction is an independent predictor of OS. Conclusion: A comparatively low PSA value could be an alternative index suggesting the optimal timing for cabazitaxel introduction.

UR - http://www.scopus.com/inward/record.url?scp=85067537429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067537429&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13444

DO - 10.21873/anticanres.13444

M3 - Article

C2 - 31177153

AN - SCOPUS:85067537429

VL - 39

SP - 3089

EP - 3094

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -